Dana-Farber Cancer Institute's Kimberly Stegmaier led a study published yesterday in PNAS that uses a "signature-based screening approach" to identify hits in neuroblastoma treatment. Her team used gene expression analysis to screen a small molecule library, and the top hit was all-trans-retinoic acid.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.